Agonists to Toll-Like Receptors (TLRs) 
SUMMARY
Agonists to Toll-Like Receptors (TLRs) have been suggested to directly impact regulatory T cells (Tregs), thereby enhancing or reversing their suppressive function. Here, in order to select TLR agonists leading to potent effector T cell responses, while minimizing Treg inhibitory function, we used a model antigen, covalently linked to an inert delivery system, combined with a large panel of TLR agonists, for the immunization of mice with an attenuated/depleted or intact Treg subset. We observed that the negative modulation of effector CD4 + T cells exerted by Tregs cannot be circumvented, whatever the TLR agonist used as adjuvant. To better understand the impact of TLR agonists on Tregs, we investigated:
(i) the TLR expression profile of highly purified CD4 + FoxP3 + Tregs, at steady state or subsequent to in vivo activation by TLR agonists, and (ii) the Treg phenotype after in vivo and in vitro activation by TLR agonists. Our results demonstrate that TLR agonists, as single signal inducers, are not able to directly activate Tregs. The phenotypic Treg activation observed in vivo, following TLR administration, does not result from cross-talk with conventional T cells but is rather a consequence of the interaction with other immune cell type(s).
INTRODUCTION
Natural regulatory T cells (Tregs) play a crucial role in maintaining peripheral T cell tolerance [1] . Moreover, antigen-specific Treg dampen immune responses in chronic infections and can be used therapeutically in cases of autoimmunity and graft-versus-host disease [2, 3] . On the other hand, there is also increasing evidence that Tregs control adaptive immune responses induced by bacteria, viruses and parasites [4] and in cancer immunity [5] . Therefore, active suppression of adaptive immune responses mediated by Tregs may constitute an obstacle to successful vaccination against infectious diseases or cancer.
Toll-like receptor (TLR) agonists are potent activators of innate immune responses, and induce DC maturation and secretion of inflammatory cytokines. Although all the members of the TLR family share several structural and functional properties, the signaling through various TLRs elicits qualitatively and quantitatively diverse immune responses [6] .
Accordingly, priming of naive T cells mediated by various DC subsets, activated through different TLRs, may lead to distinct T cell polarization [7] .
It has been recently suggested that Tregs could be directly impacted by TLR agonists [8] . The action of TLR agonists on Tregs as well as the TLR expression profile of these cells remain controversial [9] . Several studies have suggested that the actions of agonists to TLR2 or TLR8 and the resulting inflammatory context can at least transiently inhibit suppressive Treg function [10] [11] [12] . Alternatively, other investigations led to the conclusion that stimulation of Tregs in the presence of agonists to TLR4 or TLR5 would increase the Treg inhibitory activity [13, 14] . In the present work, we thus sought to determine whether the use of different TLR agonists in in vivo immunization differentially influences the inhibitory function of 
RESULTS

Adjuvant properties of different TLR agonists on the induction of CD4 + T cell responses
We recently showed that agonists to TLR3 and TLR9, but not to TLR2/6, TLR4 or TLR7, are able to induce, in a fully type I IFN-dependent and CD4 + Th-independent manner, efficient CTL responses, when co-injected with the OVA 257-264 CTL epitope, covalently linked to synthetic latex microspheres [16] . Here, we analyzed the adjuvant effect of a large panel of TLR2/6 agonist), poly(I:C) (TLR3 agonist), LPS (TLR4 agonist), polyU (Lyovec) (TLR7 agonist), R848 (TLR7 agonist) or CpG-B (TLR9 agonist), formulated with the monocationic lipid Dotap (CpG(Dotap)).
As previously observed for CD8 + T cell responses [16] , B-OVAp alone or mixed with zymozan did not induce detectable OVA-specific CD4 + T responses in WT mice ( Figure 1 ).
In contrast, poly(I:C), LPS, polyU (Lyovec), R848 or CpG(Dotap) displayed a strong adjuvant effect for the induction of IFNγ-producing CD4 + T cells, as evaluated by ELISPOT ( Figure 1A ) or by the amounts of IFNγ released by splenocytes following antigen-specific stimulation ( Figure 1B) . In IFNARko mice, antigen-specific CD4 + T cell responses were barely detectable when TLR3, TLR4 or TLR7 agonists were used as adjuvant, and was drastically decreased in the case of TLR9 agonist ( Figure 1 ).
These results allowed the identification of the agonists to TLR3, 4, 7 and particularly agonist to TLR9, as the best adjuvants for the induction of antigen-specific CD4 + T-cell effectors and indicated that their adjuvant effects are dependent on the action of type-I IFN. We further determined, at a functional level, whether Tregs limit the magnitude of CD4 + T cell responses, induced via the action of various TLR agonists. In Treg-attenuated WT mice, i.e., treated with a single dose of 1 mg of anti-CD25 mAb (PC61) [23, 24] , and then immunized with B-OVAp alone or in the presence of zymozan, no OVA-specific CD4 + T cell responses were detectable (Figure 2A and B). This result shows that the inability of this TLR agonist to induce CD4 + T cell responses is not due to a negative regulation exerted by Tregs.
Effect of
In contrast, compared to the control Ig-treated mice, in PC61-treated mice, the frequencies of OVA-specific IFNγ-producing CD4 + T cells ( Figure 2A ) and the levels of IFNγ secretion 
Indirect activation of conventional T cells and Tregs by TLR agonists
To assess whether TLR agonists could activate directly Tregs, highly purified FACS sorted CD4 + FoxP3-GFP + Tregs or total CD4 + T cell subset were stimulated for 48h in vitro in the presence of CpG, chosen as the best adjuvant in our experimental model (see Figure 1) . It has been previously reported that TLR agonists can act as co-stimulatory signals to TCR stimulation on T cells [33] . More recently, the activation of Tregs by TLR2 agonist has been also reported to occur only in the case of TCR triggering [32] . We thus tested Treg activation with either anti-CD3 ε mAb or CpG alone or in combination. Cytofluorometric analyses of S5C ).
Taken together, these results demonstrate that TLR agonists, as single signal inducers, are not able to directly activate Tregs. Moreover, Treg activation observed in vivo or in the context of non-fractionated splenocytes does not result from a cross-talk with the conventional T cells but rather seems to be mediated via a more complex interaction with other immune cell types.
DISCUSSION
T cell differentiation into Th1, Th2, Th17 or Tregs is a product of the stimulation of naive T cells, mediated by different DC subsets which are activated via distinct TLRs [7] . Although TLR agonists have numerous applications as adjuvants for prophylactic vaccination against infectious diseases and in cancer immunotherapy [43, 44] , the immunosuppressive environment of the patients with cancer or chronic infections may limit the development of such immunotherapeutics. Accordingly, depletion of Tregs in mice increases tumor-specific immunity and improves survival following tumor challenge [45] . Therefore, modulation of Tregs may represent an attractive strategy to enhance the efficacy of vaccination against pathogens or cancer cells [46] [47] [48] .
MATERIALS AND METHODS
Mice
Six to 8-week-old female C57BL/6 mice wild type or lacking the type I IFN receptor (IFNARko) [49] were obtained respectively from Janvier (Le Genest-St-Isle, France) and the Pasteur Institute (Paris, France). C57BL/6 Foxp3-GFP knock-in mice were obtained from Dr
Malissen's laboratory [50] . DEREG mice allowing the selective depletion of Foxp3-DTR-GFP + Treg cells were described previously [18] . Animals were kept under specific pathogenfree conditions in the Pasteur Institute animal facilities. All in vivo experiments were conducted according to the institutional guidelines for animal care.
Reagents and immunizations
The I-A b -restricted OVA 323-339 (ISQAVHAAHAEINEAGR) synthetized by PolyPeptide (Strasbourg, France), was covalently linked to synthetic latex beads (1 µm diameter;
Polysciences, Warrington, PA), as previously described [15, 16] . The beads coated with OVA 323-339 will be referred to as B-OVAp. Mice were immunized i.v. with 1 x 10 9 beads, either alone or in combination with 25 µg of zymosan, poly(I:C), ultrapure LPS, poly(U) (complexed to LyoVec), R848 (InvivoGen), or of CpG oligodeoxynucleotide type B (ODN-B 1826, 5'-TCCATGACGTTCCTGACGTT-3') (Proligo), administered mixed with the monocationic lipid Dotap (60 µg/mouse) (Roche Diagnostics). The anti-mouse CD25 mAb (PC61, rat IgG 1 ) and the control rat IgG 1 (CRL1912) were purified from ascitic fluids, as previously described [23, 24] . Treg depletion in DEREG mice was performed by i.p.
injections of Diphtheria Toxin (DT) (Merck Calbiochem). 
Cell isolation
Detection of TLR expression by qRT-PCR
Total RNAs was extracted from 3 x 10 5 cells/sample, using RNeasy Plus MicroKit (Qiagen).
cDNAs were synthetized by use of oligo-dT and RNase H-reverse transcriptase SuperScript II (Invitrogen). The resulting cDNA were subjected to a 35-cycle PCR amplification, using the RT² SYBR Green ROX Master Mix (SABiosciences, Tebu-Bio), performed on a 7300 RealTime PCR System (Applied Biosystems). The ready-made primer and probe sets specific to TLR-1 to TLR-9 or to the housekeeping genes, Hypoxanthine Guanine PhosphoRibosyl Transferase 1 (hgprt-1) and Glucuronidase beta (gusb) were obtained from SABiosciences. , where CT represents the cycle threshold for each qRT-PCR reaction.
In vitro T cell assays
Splenocytes ( 
Cytokine ELISA and ELISPOT assays
IFNγ contents of the culture supernatants as well as IL-6, IL-12p40, IFNα and TNFα amounts in the sera were determined by standard sandwich ELISA, as previously described [51] . IFNγ-specific ELISPOT assays were carried out as previously described [15, 16] .
Statistical analysis
Prism software (GraphPad Software, Inc.) was used to calculate statistical significance for differences of particular measurements between groups. The unpaired Student's t test was used and p values < 0.05 were considered to be statistically significant. 
